<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240617062155N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-08-10</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>effectiveness of phenytoin and Levetiracetam and valproic acid in prevention of seizure of brain hemorrahage</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of phenytoin and Levetiracetam and valproic acid in prevention of seizure of post traumatic brain hemorrahage</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-08-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>225</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/77557</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in this study will be done using block randomization method. In this way, 225 blocks of 3 were created randomly using randomization.com online software by the plan's statistical consultant and sealed in 225 envelopes with aluminum cover and numbered in the order of creation. Then, during the implementation of the plan, the created sequences will be removed from the envelopes and the patients will be assigned to groups A, B and C based on the sequence of each block, Blinding description: Patients will be assigned to each treatment based on block randomization method.The study procedure and the requirement to receive an anticonvulsant drug after severe traumatic brain injury, which is one of the 3 injectable drugs available in Iran which are also the subject of our study, will be explained to patients or their legal guardians, and informed consent will be obtained. However, the patients or their legal guardian will not be aware of the type of drug received (out of the 3 drugs). Additionally, the medical intern, who is responsible for collecting data, will not be aware of the drug received and will recognize them into groups A, B, or C ; the project manager and the data analyst will be aware of the type of drug received by the patients.</study_design>
      <phase>3</phase>
      <hc_freetext>traumatic intracerebral haemorrhage.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In this group, the patients are treated with the anticonvulsant drug phenytoin (Caspian-Iran) with a loading dose of 20 mg/kg and injection within one hour and a maintenance dose of 5 mg/kg every day, which the patients first receive injectable drug for 24 to 48 hours and then They receive oral drug. Phenytoin is taken from Caspian Tamin-Iran pharmaceutical company. It is one of the three common anti-seizure medications used in Iran to prevent seizures caused by traumatic brain injury. Intervention 2: Intervention group 2: In this group, patients are treated with the anticonvulsant drug Levetiracetam (Arang-Iran) with a loading dose of 20 mg/kg and an injection within one hour and a maintenance dose of 10 to 20 mg/kg every day. They receive for 24-48 hours injectable and then oral medicine. Levetiracetam is taken from Arang-Iran Daro Darman pharmaceutical company . It is one of the three common anti-seizure medications used in Iran to prevent seizures caused by traumatic brain injury. Intervention 3: Intervention group 3: In this group, 15 mg/kg of the anticonvulsant drug sodium valproate (Arang-Iran) injection is first prescribed for patients, and the maintenance dose is 15 mg/kg in 2 to 3 divided doses every day. Patients first receive injectable medicine for 24 to 48 hours and then orally. The sodium valproate  is  taken from Daro Derman Arang-Iran pharmaceutical company.It is one of the three common anti-seizure medications used in Iran to prevent seizures caused by traumatic brain injury.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Benyamin Beyrami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar-e-azam complex, Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3314 4712</telephone>
        <email>benyamin.medicine@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Benyamin Beyrami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar-e-azam complex, Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3314 4712</telephone>
        <email>benyamin.medicine@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Head trauma requiring prophylactic anticonvulsant treatment</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
History of epilepsy
Allergy to the studied drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S06.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Focal traumatic brain injury</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In this group, the patients are treated with the anticonvulsant drug phenytoin (Caspian-Iran) with a loading dose of 20 mg/kg and injection within one hour and a maintenance dose of 5 mg/kg every day, which the patients first receive injectable drug for 24 to 48 hours and then They receive oral drug. Phenytoin is taken from Caspian Tamin-Iran pharmaceutical company. It is one of the three common anti-seizure medications used in Iran to prevent seizures caused by traumatic brain injury</i_keyword>
      <i_keyword>Intervention group 2: In this group, patients are treated with the anticonvulsant drug Levetiracetam (Arang-Iran) with a loading dose of 20 mg/kg and an injection within one hour and a maintenance dose of 10 to 20 mg/kg every day. They receive for 24-48 hours injectable and then oral medicine. Levetiracetam is taken from Arang-Iran Daro Darman pharmaceutical company . It is one of the three common anti-seizure medications used in Iran to prevent seizures caused by traumatic brain injury</i_keyword>
      <i_keyword>Intervention group 3: In this group, 15 mg/kg of the anticonvulsant drug sodium valproate (Arang-Iran) injection is first prescribed for patients, and the maintenance dose is 15 mg/kg in 2 to 3 divided doses every day. Patients first receive injectable medicine for 24 to 48 hours and then orally. The sodium valproate  is  taken from Daro Derman Arang-Iran pharmaceutical company.It is one of the three common anti-seizure medications used in Iran to prevent seizures caused by traumatic brain injury</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Seizure. Timepoint: The first day to a week after starting the study. Method of measurement: Clinical observation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-05-18</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Payambar-e-azam complex, Sardasht Town Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
